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1 Minimalist Protein Engineering of an Aldolase Provokes
2 Unprecedented Substrate Promiscuity
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9 ABSTRACT: Application of aldolases for the asymmetric synthesis of multifunctional
10 chiral products is hampered by their reputed strict nucleophile (=aldol donor) speciﬁcity
11 owing to a mechanistic requirement for creating a carbanion nucleophile in aqueous
12 medium. Here we report that a minimalist engineering can extensively broaden the
13 substrate scope of native D-fructose-6-phosphate aldolase (FSA) from Escherichia coli, for
14 which hydroxyacetone is the most proﬁcient substrate, to accept an unprecedented wide
15 variety of alternative nucleophiles. By single- or double-space-generating mutations using
16 simple conservative Leu to Ala replacement of active site residues, we found enzyme
17 variants to eﬃciently convert larger ketols and bioisosteric ether components with up to
18 seven skeletal atoms, including linear and branched-chain structures. All reactions occurred
19 with full retention of the natural D-threo diastereospeciﬁcity. These FSA variants open new
20 avenues toward the synthesis of novel product families that hitherto were inaccessible by
21 biological catalysis.
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23 ■ INTRODUCTION
24 The concept of enzyme promiscuity, reﬂecting on an enzyme’s
25 capability to catalyze more than one chemically distinct reaction
26 type by stabilizing diﬀerent transition states (catalytic
27 promiscuity) or to show ambiguity in the conversion of several
28 substrates while involving the same transition state (substrate
29 promiscuity, also called substrate ambiguity), has aroused
30 substantial interest recently because of its implications in the
31 natural mechanisms for the divergent evolution of new enzyme
32 functions from a common progenitor.1 Indeed, adaptation of an
33 enzyme to degrade xenobiotics or to convert cognate
34 metabolites may result from only few mutations, even as little
35 as a single replacement in the active site.2 The utilization of
36 selected enzymes to catalyze reactions on a plethora of non-
37 natural substrates is the core principle for a growing sustainable
38 bioproduction industry,3 underscoring the notion that some
39 enzymes are catalytically much more ﬂexible than originally
40 assumed.
41 Aldolases catalyze a highly ordered, stereoselective addition
42 of a carbon nucleophile (the aldol donor), which typically is a
43 ketone enolate or transiently formed enamine equivalent, to a
44 carbonyl electrophile (the aldol acceptor), which typically is an
45 aldehyde. This carboligation process leads to the formation of
46 up to two adjacent chiral centers of known absolute
47 conﬁguration. Whereas most aldolase-type enzymes tolerate a
48 broad variety of non-natural aldehyde electrophiles with good
49 catalytic rates, they generally share high substrate speciﬁcity for
50their nucleophile, as reiteratively documented for a broad
51variety of distinct aldolases from various sources.4 Even small
52structural variations in the nucleophile, such as replacing
53ethanal for propanal,5 1,3-dihydroxyacetone phosphate
54(DHAP) for a bioisosteric phosphonate,6 or pyruvate for
55ﬂuoropyruvate,7 with speciﬁc aldolases resulted in a decrease of
56activity of up to several orders of magnitude, reﬂecting the
57strong inﬂuence of steric and electronic factors on the intricate
58binding environment required to stabilize the highly ordered
59bisubstrate transition state. Only subtle variations in the
60nucleophilic substrate structure were found to be permissible,
61such as from protein engineering attempts4c to change the
62substrate speciﬁcity of D-fructose-6-phosphate aldolase (FSA;
63 s1Scheme 1) from hydroxyacetone (1) to dihydroxyacetone
64(DHA)8 or to hydroxyethanal,9 that of transaldolase BF178Y
Received: December 14, 2015
Revised: January 29, 2016
Scheme 1. FSA Catalysis for the Cleavage of D-Fructose 6-
Phosphate (Fru6P) into D-Glyceraldehyde 3-Phosphate
(GA3P) and Dihydroxyacetone (DHA)
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65 from DHA to 1,10 or that of L-rhamnulose-1-phosphate aldolase
66 from DHAP to DHA.11
67 We present herein an unprecedented, wide expansion of the
68 nucleophilic substrate tolerance of FSA by structure-guided
69 rational protein engineering to tune the substrate binding site
70 for larger nucleophile structures that could potentially carry
71 additional functionalization.
72 We have found that a single- or double-active-site mutation
73 was suﬃcient to allow productive binding of a large number of
74 non-natural nucleophilic components, unlocking an entry to a
75 broad variety of chiral products that expand widely beyond the
76 horizon of currently known biocatalysts.
77 ■ RESULTS AND DISCUSSION
78 FSA is a class I aldolase that reversibly cleaves D-fructose 6-
79 phosphate (Fru6P) via covalent substrate activation by Schiﬀ
f1 80 base formation at K85 (Figure 1).13 Wild-type FSA shows the
81 highest activity with 1 and 1-hydroxy-2-butanone (2) as aldol
82 nucleophiles10,14 but tested negative with up to 150 mM of the
83 higher homologous 1-hydroxy-2-pentanone (3). To increase
84 the substrate tolerance of wild-type FSA for larger nucleophile
85 structures, mutagenesis was directed at carefully selected active-
86 site residues lining the substrate binding pocket. The crystal
87 structure of FSA had been solved without liganded substrate
88 (PDB entry 1l6w).13 For better guidance, we have built a model
89 by inserting the Fru6P structure from the substrate-liganded
90 transaldolase B from E. coli (PDB entry 3s1v),12 taking
91 advantage of the very high structural homology among those
92 enzymes (Figure 1A). The model suggests that the aliphatic
93 portion of the preferred nucleophiles 1/2 will be in contact
94 with the side chains of L107, A129, L163, and A165 that jointly
95 form a hydrophobic binding pocket at the distal end of the
96 active site. For a mutagenesis to increase the substrate-
97 accessible volume, the selection included both bulky residues
98 (i.e., L107, L163, and A129) that could reduce space
99 restrictions for donor binding and residues that in earlier
100 studies were identiﬁed to beneﬁt the overall kinetic competence
101 of the enzyme in the direction of synthesis (i.e., L107 and
102A129).9,15 For an evaluation of variants toward a substrate
103tolerance beyond the C4 donor 2, we ﬁrst selected a series of
104higher homologous ketols having longer aliphatic chains (3−5;
105C5−C7).
16 We chose to expand the substrate up to the C7 ketol
106as the minimum chain length that allows investigating
107systematically the eﬀect of branching, using only structures
108that were constitutional isomers and thus would pose similar
109requirements in total ligand volume.
110In a ﬁrst round, single-site variants L107A, A129G, and
111L163A (Figure 1) were assayed against wild-type FSA or A129S
112variant as a reference, for their ability to catalyze an aldol
113 f2addition of the 1-hydroxyalkanones (2−5) (Figure 2A) to 3-
114hydroxypropanal (16), furnishing stable six-membered-ring
115 t1structures (Table 1, 18−21β,α). Both reaction components
116were chosen to be prochiral to avoid complications from kinetic
117enantiomer selectivity. The methylene unit introduced by 16 is
118a useful reporter for the product stereochemistry by proton
Figure 1. (A) Illustration of the substrate binding based on the X-ray
crystal structure of wild-type FSA (PDB 1l6w) and its L107A/L163A
variant. Active-site residues that are lining the substrate pocket are
shown as light gray sticks. The inner surface of the cavity is frontally
sliced for better inspection; the cavity opens to the left toward bulk
solvent. The substrate is modeled by ﬁtting the Fru6P structure from
the highly similar complex of transaldolase (PDB 3s1v)12 to form a
Schiﬀ base complex with K85. Substrate parts corresponding to
electrophilic and nucleophilic moieties are shown in light orange and
yellow, respectively. (B) Representation of the L107A/L163A double-
site mutant showing the increased binding pocket that will take up the
aliphatic substrate portion of extended nucleophile analogues (3−15).
Figures were prepared using PyMOL.
Figure 2. (A) Panel of substrates that can replace DHA with wild-type
FSA (1, 2), as well as non-natural substrate analogues (3−15)16
considered for probing the substrate promiscuity of FSA variants.
Structures are grouped in three series comprised of linear and
branched-chain ketols and DHA monoalkyl ethers. (B) Variant
screening for conversion of 1-hydroxy-2-alkanones 2−10. (C) Data
for 1,3-dihydroxypropanone monoalkyl ethers 11−15. Mixtures of 100
mM ketol and 150 mM 16 were reacted in triethanolamine buﬀer (50
mM, pH 8, 0.2 mL) in the presence of 0.1 mg of enzyme, and the
progress was monitored by HPLC. Ketols 11−14 are bioisosteric with
3−5 and 8, respectively, and these columns are vertically aligned for
better comparison.
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119 NMR spectroscopy.10 All nucleophiles larger than 2 were only
120 partially converted by variants designed for increased substrate
121 space (Figure 2B); compound 4 was accepted only by the Leu
122 mutants, and the largest probe 5 was converted by the L163A
123 variant only. The L163A variant consistently showed the
124 highest rates with all nucleophiles, causing complete conversion
125 of 2 and 3 already during the initial 2 h reaction phase and
126 nearing complete conversion within 24 h. For the second
127 round, we constructed all double-site combinations starting
128 with the most successful L163A variant, and the potentially
129 beneﬁcial L107A/A129G combination. All variants showed
130 good to excellent activity with 2−4, while 5 was converted only
131 by those incorporating at least the L163A replacement.
132 Remarkably, only the L107A/L163A mutant achieved high
133 conversion already after short reaction times. In a third stage, all
134 positive mutations were combined into triple-site variants. Only
135 the variant L107A/A129S/L163A showed excellent activity
136 with 3−5, practically indistinguishable from its L107A/L163A
137 progenitor, whereas that incorporating the A129G mutation
138 displayed considerably lower activity. Any combination of the
139 A129G with the L107A mutation has a detrimental eﬀect on
140 catalysis, possibly because of higher backbone mobility arising
141 from placing a Gly residue next to the void created by the L163
142 replacement. In comparison, combination of the A129G with
143 the L163A exchange is practically neutral.
144 As an increasing steric challenge for substrate binding, we
145 further tested a set of isomeric ketols that contained a single
146 (6−8) or complete terminal branching (9 and 10). All substrate
147 analogues having at least one methylene group between the
148 carbonyl and the branch point (7, 8, and 10) were converted by
149 those FSA variants, incorporating the L163A mutation with at
150 least one additional space-generating variation, albeit at
151 substantially reduced reaction rates in comparison to the
152corresponding straight-chain isomers (Figure 2B). Branching
153directly adjacent to the ketone (6, 9) was not tolerated by any
154of the FSA variants. Failure to deliver an aldol product most
155likely is caused by steric interference during one of the early
156steps in catalysis.12,17 Although an increasing level of alkyl
157branching, up to the neopentyl situation (10), leads to a more
158compact size and reduced molecular volume for this substrate
159part, it appears that linear chains beneﬁt from their higher
160conformational ﬂexibility in adapting to the binding cavity
161created by mutagenesis. Generally, variant L107A/L163A
162seems to be the superior catalyst design among the variations
163tested.
164In addition to a mere size increase by carbon chain extension,
165we next explored the set of engineered FSA for their ﬂexibility
166toward ketol nucleophiles with modiﬁed chemical functionality
167(Figure 2C). We tested a series of DHA ether derivatives 11−
16814 analogous to the alkanones,16 and also included the allyl
169compound 15 to facilitate speciﬁc postsynthetic modiﬁcations.
170We chose the ether series for several reasons: (i) increased
171carbonyl electrophilicity, (ii) the ability to gain dipolar contacts
172to the donor binding site at similar conformational ﬂexibility,
173(iii) their rather high chemical stability, and (iv) their frequent
174occurrence as a structural unit in many important natural
175products and bioactive drugs. Methyl ether 11 as the smallest
176member showed good reaction rates for all variants, even for
177wild-type FSA. The latter was somewhat surprising, because the
178isosteric alkanone 3 is no substrate for wild-type FSA. Higher
179homologous linear ethers 12 and 13 were converted well by all
180double-site (or higher) variants, with a reactivity pattern similar
181to that observed for the alkanone series, but were not tolerated
182by wild-type FSA. Isopropyl ether 14 was also converted,
183although at reduced reaction rates that did not yield complete
184conversion within 24 h.
185Initial rates (v0) measured for the top variants from each
186generation indicate that the ethers appeared to be somewhat
187 f3more reactive than the corresponding alkanones (Figure 3).
188This was conﬁrmed by a direct competition experiment using
189an equimolar mixture of ketols 3/11 for addition to 16
190catalyzed by the L107A/L163A variant. Reaction monitoring by
191in situ NMR analysis revealed the ether 11 indeed showed
192about 1 order of magnitude higher initial reactivity than 3 (i.e.,
Table 1. Preparative Synthesis of Aldol Products Using
Catalysis by FSA Variant L107A/L163A for Addition of
Artiﬁcial Nucleophiles to Nonchiral 3-Hydroxypropanala
nucleophile product R isolated yield (%)
1 17 CH3 87
b
2 18 CH2CH3 89
b
3 19 (CH2)2CH3 75
4 20 (CH2)3CH3 76
5 21 (CH2)4CH3 50
6 22 CH(CH3)2 c
7 23 CH2CH(CH3)2 28
8 24 (CH2)2CH(CH3)2 25
9 25 C(CH3)3 d
10 26 CH2C(CH3)3 25
11 27 CH2OCH3 89
12 28 CH2OCH2CH3 82
13 29 CH2O(CH2)2CH3 28
14 30 CH2OC(CH3)2 30
15 31 CH2OCH2CHCH2 45
aMixtures of 150 mM ketol and 100 mM 16 were reacted in GlyGly
buﬀer (50 mM, pH 8.5, 10 mL) in the presence of 15 mg of variant
L107A/L163A, and products were isolated by silica gel chromatog-
raphy. In each case, dr > 98% was assessed by 1H NMR analysis.
bIdentical products have been isolated using wild-type FSA (see ref
10). cNo conversion. dYield not determined.
Figure 3. Comparison of initial rates for top FSA variants with non-
natural substrates. Mixtures of 100 mM ketol and 150 mM 16 in
triethanolamine buﬀer (50 mM, pH 8, 1 mL) were reacted in the
presence of 60−200 μg of enzyme, and progress was monitored by
HPLC (<10% conversion). Data are the mean of at least triplicate
experiments ± standard error of the mean.
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193 1.8 × 10−4 vs 2.2 × 10−5 mmol min−1 mg−1; see Figure S4 in
194 the Supporting Information) and yielded a higher overall
195 competitive conversion (89% vs 17%).
196 Wild-type FSA had previously been demonstrated to catalyze
197 a highly D-threo stereoselective carboligation, practically
198 irrespective of structural variations in the hitherto known
199 nucleophilic (DHA, 2, 3, glycolaldehyde) and electrophilic
200 aldol components.10,14,18 To assess the level of stereoselectivity
201 in the carboligation with non-native nucleophiles 2−15,
202 products 18−31 were isolated (25−89% yield) from
203 preparative reactions catalyzed by the L107A/L163A variant
204 (Table 1). Analysis of crude reaction mixtures by HPLC and
205 NMR analysis revealed that only a single type of stereoisomer
206 was formed in all cases (see pp S22−S57 in the Supporting
207 Information). Because both aldol substrates were chosen to be
208 prochiral for simplicity, unambiguous conﬁgurational determi-
209 nation of the aldol products required correlation with an
210 established chirality. We note that products 19−31 were
211 hitherto inaccessible by biocatalytic routes and yet are unknown
212 from natural sources for comparison. The assignment of the
213 absolute D-threo conﬁguration created by catalysis of variant
214 L107A/L163A was therefore conﬁrmed by the analogous
215 addition of 3 to enantiopure D-glyceraldehyde (32) for an
216 internal chiral reference, which furnished the expected adduct
s2 217 as a single diastereomer (Scheme 2 and Figure S16 in the
218 Supporting Information). Also, exemplary addition of 2 to
219 propanal as a simple, nonfunctionalized aliphatic acceptor
220 furnished the corresponding product, demonstrating the broad
221 utility of the method. However, stereoselectivity was incom-
222 plete with a 10:1 ratio for threo/erythro conﬁguration (Scheme
223 2 and Figure S17 in the Supporting Information),10,19 which
224 may originate from a less speciﬁc binding orientation of the
225 unsubstituted aliphatic chain.
226 A critical mutation of the engineered FSA is the L163A
227 replacement that creates additional space in a direction where
228 an enlargement of the substrate apparently can be well
229 accommodated in a rather extended conformation, while the
230 L107A mutation seems to require a less favorable bent
231 orientation of the ketol. In the L107A/L163A double-site
232 variant, the contiguous extra void now expanding to second-
233 sphere protein residues (e.g., F57, Y127, A164, and S183; see
234 Figure 1B) enables binding of ketols with chain lengths (at
235 least) up to C7. It is noteworthy that in comparison to the
236 activity of wild-type FSA with 2 (i.e., the best substrate together
237 with 1) the engineered L107A/L163A variant is equally
238eﬃcient with the branched-chain C7 ketol 8 and even more
239eﬃcient with the linear C7 ketol 5. This points out that the
240expanded substrate binding space, which plausibly will be ﬁlled
241with water molecules in the native state, does not interfere with
242the overall kinetics of substrate binding and release. We
243interpret the success of our design strategy to be due to the fact
244that the catalytic machinery remained intact; in particular, the
245mutations did not interfere with (i) the covalent substrate
246activation by Schiﬀ base formation at K85 or (ii) the catalytic
247function of acid−base residue Tyr131; (iii) in addition, it did
248not induce a disturbing change or switch of the H-bonding
249network.20
250Mutagenic creation of a larger cavity extending from the
251donor-binding pocket may be expected to destabilize the rigid
252hydrophobic core surrounding the FSA active site (Tm = 87.0
253°C).21 Interestingly, the more hidden L107A modiﬁcation (Tm
254= 90.4 °C) actually leads to protein stabilization, as judged by
255diﬀerential scanning ﬂuorimetry, whereas the stability of the
256 f4L163A variant (Tm = 78.4 °C) substantially decreased (Figure 4
257and Table S4 in the Supporting Information). Both
258consequences seem independent, as in the combined L107A/
259L163A mutant (Tm = 81.4 °C) the eﬀect apparently is additive.
260Considering that engineered enzymes are often compromised
261by low stability,22 which hampers their practical use, the
262outcome for the new FSA variants is signiﬁcant, since they
263retain high stability for preparative applications.
264■ CONCLUSION
265The unprecedented realization of wide substrate promiscuity of
266an aldolase for the nucleophilic component provides insight
267into the malleability of protein active sites, even in the case of
268aldolases that are generally perceived to have strict speciﬁc-
269ity.4,23 This is highly relevant to our understanding of enzyme
270evolution and should improve the general knowledge of
271substrate−protein interactions for future endeavors in protein
272engineering. The modular nature of the enzymatic aldol
273synthesis is amenable to considerable structural variation,
274previously only for the electrophilic component but now also
275for the nucleophilic component, which allows the targeting of a
276largely extended range of product structures in a combinatorial
277fashion. We have shown that this critical feature in synthetic
278versatility allows the rapid, protecting group free construction
279of unnatural carbohydrate analogues, exempliﬁed by 17−31.
280We anticipate that the FSA mutants will be useful for the
281asymmetric synthesis also of more generic, non-carbohydrate
Scheme 2. Absolute D-threo Diastereospeciﬁcity for FSA
Variant L107A/L163A Using Enantiopure D-Glyceraldehyde
32 and Observation of Incomplete Speciﬁcity upon Addition
to Propanal 34a
aMixtures of 150 mM ketol and 100 mM aldehyde were reacted in
GlyGly buﬀer (50 mM, pH 8.5, 10 mL) upon catalysis by variant
L107A/L163A, and products were isolated by silica gel chromatog-
raphy.
Figure 4. Changes in the unfolding transition temperature (ΔTm) in
reference to wild-type FSA. A negative ΔTm value indicates a
destabilizing mutation, and a positive ΔTm value shows stabilization.
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282 chiral building block structures (e.g., 35) that expand widely
283 beyond the horizon of currently known biocatalysts. The
284 designed FSA variants are expected to stimulate innovative
285 biotechnological applications, including the stereoselective
286 access to novel product families that hitherto have not been
287 readily available for pharmaceutical study.
288 ■ EXPERIMENTAL SECTION
289 General Procedure for Enzymatic Syntheses. Lyophi-
290 lized FSA L107A/L163A variant (15 mg) was added to a
291 solution (10 mL total reaction volume) containing the
292 respective ketol (150 mM) and aldehyde components (100
293 mM) in glycyl-glycine buﬀer (50 mM, pH 8.5), and the
294 resulting mixture was incubated at room temperature with
295 monitoring at regular intervals by TLC (chloroform/methanol
296 5/1). Depending on the rate of aldehyde consumption,
297 completed reactions were worked up after 24−48 h by
298 lyophilization of the crude reaction mixture. The residue was
299 puriﬁed by silica gel column chromatography using chloro-
300 form/methanol (15/1 to 5/1) as eluent to provide the pure
301 aldol products.
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